A study led by Boston University School of Medicine has identified a novel approach to create an unlimited number of human red blood cells and platelets in vitro. In collaboration with Boston University School of Public Health (BUSPH) and Boston Medical Center (BMC), the researchers differentiated induced pluripotent stem (iPS) cells into these cell types, which are typically obtained through blood donations.
Home healthcare and the use of medical devices outside of the professional healthcare environment are on the rise. Modern medicine allows us to live longer and provides those with chronic diseases the ability to receive medical care at home. Examples of home-use devices are oxygen concentrators, hospital beds, sleep apnea monitors, body-worn nerve and muscle stimulators, and dialysis machines, just to name a few.
Medtronic, Inc. (NYSE: MDT) is expanding its market-leading portfolio of products for endovascular aortic repair in the United States with two new medical devices: the company recently received approval from the U.S. Food and Drug Administration (FDA) for the Endurant II Aorto-Uni-Iliac (AUI) Stent Graft System and the FDA’s 510(k) clearance for the Sentrant Introducer Sheath.
Uscom (ASX: UCM) Uscom Limited today signed a deed to acquire all assets of Pulsecor Limited. Pulsecor Limited is a New Zealand company which has developed novel non-invasive central blood pressure measurement methods pioneered at the Weill Cornell Medical College in New York.
The technology at the heart of the next generation of medical devices is critical to our ability to offer comprehensive care in the coming decades. While our current systems of care have served us well thus far, they are crumbling under the pressures of modern expectations of care, economics, scale, and the sheer breadth of medical science.
Charlotte Based Compression And Vacuum Therapy Technology Helps Train Cyclist In Race Across AmericaMay 29, 2013 11:30 am | by PR Newswire | News | Comments
Austrian Cyclist Gerald Bauer will be directly benefiting from Charlotte based HYPOXI therapy and equipment to give him a possible racing edge in the Race Across America. Gerald will specifically use the Charlotte HYPOXI Multispectrum S120 device one week prior to the race and each day after the race. Dr. Fedor Fomin of HYPOXI will be providing the therapy.
Study of the Use of Control Catheters with the Sensei X Robotic System for the Treatment of Atrial FibrillationMay 29, 2013 8:00 am | by The Associated Press | News | Comments
Hansen Medical, Inc., a global leader in intravascular robotics, today announced that it has received conditional approval from the U.S. Food and Drug Administration to change the study design of its ARTISAN-AF Trial, a pivotal clinical trial evaluating the use of Hansen Medical's Artisan® family of Control Catheters with its Sensei® X Robotic Catheter System for treatment of Atrial Fibrillation, the most common cardiac arrhythmia.
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that its subsidiary Hotspur Technologies, Inc., which Teleflex acquired in June 2012, completed CE marking requirements to market the company’s Arrow ® GPSCath ® Balloon Dilatation Catheters to the European Union.
The Food and Drug Administration said Thursday it approved a new blood test from Roche to help doctors diagnose diabetes. The Cobas Integra 800 is a blood test that measures a patient's average blood sugar level over the previous three months. In particular, the test measures an oxygen-carrying blood component known as hemoglobin.
Aptus Endosystems, Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its 28mm Tip Reach Heli-FX™ Guide. A line extension of the original Heli-FX System, the new product enhances treatment of wide neck abdominal aortic aneurysms (AAA).
OrbusNeich Launches World's First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting StentsMay 27, 2013 3:00 am | by The Associated Press | News | Comments
OrbusNeich today launched the world's first dual therapy stent - the COMBO Dual Therapy Stent - to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard of care for the treatment of coronary artery disease...
Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced the completion of its acquisition of substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions.
A new investigational device—the Helio System (TF-FA) —being developed for use with the Sapien XT Transcatheter Heart Valve was successfully deployed in all four patients in a small, first-in-human feasibility study of its use in high-risk aortic insufficiency reported at EuroPCR 2013.
Transcatheter aortic valve implantation is effective and safe in Asian patients, according to early experience based on first results from a multicentre Asian registry reported at EuroPCR 2013. "TAVI has become a treatment option for selected patients with symptomatic severe aortic stenosis. But current data are virtually all from North American or European centres," Paul Chiam told the conference.
PARIS & MENLO PARK, Calif.--(BUSINESS WIRE)--May 24, 2013--CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced the transmission of a live satellite feed of a clinical case using the first-of-its-kind catheter-based Parachute ®...
Reason for Recall: Cook Medical received a small number of complaints that the delivery system of the device had separated at the tip of the inner catheter. Potential adverse events that may occur in cases where the inner deliver catheter breakage...
Hansen Medical to Exhibit Magellan Robotic System at 2013 Vascular Annual Meeting of the Society for Vascular SurgeryMay 23, 2013 4:03 pm | by The Associated Press | News | Comments
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will exhibit its Magellan Robotic System at the 2013 Vascular Annual Meeting® of the Society for Vascular Surgery from May 30 - June 1 at the Moscone West Convention Center in San...
ST. PAUL, Minn.--(BUSINESS WIRE)--May 23, 2013--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), presented 30-day results from its ORBIT II study of coronary artery disease in a late-breaking presentation at the 2013 European Association of Percutaneous Cardiovascular Interventions (EuroPCR)...
Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity Renal Denervation System for Treatment-Resistant HypertensionMay 23, 2013 6:06 am | by The Associated Press | News | Comments
Medtronic, Inc., today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter-based procedure to reduce activity of the renal (kidney) nerves, which are part of the sympathetic nervous system and help regulate blood pressure.
InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control GroupMay 23, 2013 6:00 am | by PR Newswire | News | Comments
InspireMD, Inc., the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients.
Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013May 23, 2013 4:30 am | by PR Newswire | News | Comments
SAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary...
One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation TechnologyMay 23, 2013 4:15 am | by The Associated Press | News | Comments
ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 23, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the company’s EnligHTN ™ Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after...
New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation SystemMay 22, 2013 12:20 pm | by PR Newswire | News | Comments
PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™ Renal Denervation...
CardioKinetix Announces Positive Clinical Data Showing Consistent Compelling Positive Results for Patients Treated with Minimally Invasive Structural Heart Device for Heart FailureMay 22, 2013 11:00 am | by The Associated Press | News | Comments
PARIS & MENLO PARK, Calif.--(BUSINESS WIRE)--May 22, 2013--CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced results of a meta-analysis study of the first-of-its-kind catheter-based Parachute ® Ventricular Partitioning Device....
Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments has drawbacks, including the risk of side effects. A new study from MIT analyzes the potential usefulness of a new treatment that combines the benefits of angioplasty balloons and drug-releasing stents, but may pose fewer risks.